Indaptus Therapeutics, Inc. — Form 8-K Summary
Reporting date: September 29, 2026 (filed September 30, 2026). The filing reports an update to a previously announced private placement; it does not report quarterly or annual financial results.
Transaction and key financial terms
- Under a September 8, 2026 Stock Purchase Agreement, the company agreed to sell common stock in a private placement for approximately $24.0 million in aggregate gross proceeds, before offering expenses.
- The filing does not state that the placement has closed or that proceeds have been received. It provides no revenue, profit, cash-flow, margin, debt, or liquidity figures.
Material change and conditions
- On September 29, the company and purchasers extended the applicable closing outside date from September 29 to October 16, 2026.
- The company may defer and coordinate purchaser closings until applicable closing conditions are satisfied or waived, but no later than October 16, unless the company and the applicable purchaser agree otherwise in writing.
- Purchaser funding deadlines and certain related termination rights were also extended to October 16. Other terms of the Purchase Agreement remain unchanged.
Outlook, risks, and investor items to verify
- Completion remains subject to the Purchase Agreement’s closing conditions, which may be satisfied or waived. The filing gives no assurance that all purchasers will fund or that the transaction will close by the extended deadline.
- Investors should verify whether and when the placement closed, the final gross and net proceeds, the number of shares issued and resulting dilution, and whether any further extensions or amendments occurred.